Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Japan”

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)Recruiting
NCT06824467Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
United States, Argentina, Australia, Belgium, Brazil +23 more
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo NodularisTerminated
NCT06527404Phase 3Updated Jul 27, 2026
Sponsor: Amgen
Prurigo Nodularis
United States, Argentina, Australia, Austria, Belgium +25 more
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)Recruiting
NCT06952504Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Endometrial Cancer
United States, Argentina, Australia, Austria, Belgium +29 more
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid TumorsRecruiting
NCT07660055Phase 1Updated Jul 27, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer · Non-small Cell Lung Cancer (NSCLC) · Gastric/Gastroesophageal Junction (GEJ) Cancer · Bladder Cancer
Australia, Canada, Japan
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001Active Not Recruiting
NCT01760005Phase 2, Phase 3Updated Jul 27, 2026
Sponsor: Washington University School of Medicine
Alzheimers Disease · Dementia · Alzheimers Disease, Familial
United States, Argentina, Australia, Brazil, Canada +10 more
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruiting
NCT06072781Phase 3Updated Jul 27, 2026
Sponsor: Verastem, Inc.
Low Grade Serous Ovarian Cancer
United States, Australia, Belgium, Canada, Denmark +11 more
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid ArthritisCompleted
NCT03025308Phase 3Updated Jul 27, 2026
Sponsor: Alfasigma S.p.A.
Rheumatoid Arthritis
United States, Argentina, Australia, Belgium, Bulgaria +27 more
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Recruiting
NCT06312176Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +35 more
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruiting
NCT05894239Phase 3Updated Jul 27, 2026
Sponsor: Hoffmann-La Roche
Metastatic Breast Cancer
United States, Argentina, Australia, Belgium, Brazil +24 more
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)Recruiting
NCT07570173Phase 2, Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
B-cell Acute Lymphoblastic Leukemia
Denmark, Israel, Italy, Japan, Netherlands +1 more
Fasenra Pediatric Japan Post-Marketing Study(PMS)Active Not Recruiting
NCT06427876N/AUpdated Jul 27, 2026
Sponsor: AstraZeneca
Bronchial Asthma
Japan
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid TumorsRecruiting
NCT07403721Phase 1Updated Jul 27, 2026
Sponsor: Amgen
Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
United States, Australia, Belgium, Canada, China +4 more
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaActive Not Recruiting
NCT03298451Phase 3Updated Jul 27, 2026
Sponsor: AstraZeneca
Hepatocellular Carcinoma
United States, Brazil, Canada, China, France +12 more
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic CancerRecruiting
NCT07409272Phase 3Updated Jul 27, 2026
Sponsor: Astellas Pharma Global Development, Inc.
Pancreatic Cancer · Metastatic Pancreatic Cancer · Metastatic Pancreatic Adenocarcinoma
United States, Japan
Verification Study of the Effects of Consumption of the Test Food on the Musculoskeletal SystemNot Yet Recruiting
NCT07729657NAUpdated Jul 27, 2026
Sponsor: Bloomage Biotechnology Corp., Ltd.
Healthy Japanese Individuals
Japan
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With SeizuresRecruiting
NCT04715646Phase 3Updated Jul 27, 2026
Sponsor: UCB Biopharma SRL
Epilepsy
United States, Belgium, Czechia, France, Germany +6 more
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)Recruiting
NCT07318558Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Neoplasms · Ovarian Cancer
United States, Argentina, Australia, Austria, Belgium +23 more
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)Active Not Recruiting
NCT05269394Phase 2, Phase 3Updated Jul 27, 2026
Sponsor: Washington University School of Medicine
Alzheimers Disease · Dementia · Alzheimers Disease, Familial
United States, Argentina, Australia, Brazil, Canada +11 more
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruiting
NCT06772623Phase 1, Phase 2Updated Jul 27, 2026
Sponsor: AbbVie
Non Small Cell Lung Carcinoma
United States, Belgium, China, France, Germany +9 more
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseRecruiting
NCT07064473Phase 3Updated Jul 27, 2026
Sponsor: Boehringer Ingelheim
Diabetes Mellitus, Type 2 · Hypertension · Cardiovascular Diseases
United States, Argentina, Australia, Austria, Belgium +46 more
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Recruiting
NCT06841354Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +29 more
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's DiseaseActive Not Recruiting
NCT05668013Phase 2Updated Jul 27, 2026
Sponsor: Teva Branded Pharmaceutical Products R&D LLC
Crohn Disease · Colitis, Ulcerative
United States, Austria, Bulgaria, Czechia, Georgia +11 more
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderRecruiting
NCT06951698Phase 3Updated Jul 27, 2026
Sponsor: Bristol-Myers Squibb
Bipolar-I Disorder With Mania or Mania With Mixed Features
United States, Argentina, Australia, Bulgaria, Hungary +4 more
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With SchizophreniaRecruiting
NCT06882785Phase 3Updated Jul 27, 2026
Sponsor: Bristol-Myers Squibb
Schizophrenia
Japan
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Recruiting
NCT06393374Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple-Negative Breast Cancer
United States, Argentina, Australia, Austria, Belgium +26 more

Previous page Next page